Dr. Rongbin Li | Cancer Biology | Best Researcher Award
Doctorate, at Peking University, China.
Dr. Rongbin Li is a dynamic and emerging immunologist affiliated with the Department of Immunology, School of Basic Medical Sciences, and NHC Key Laboratory of Medical Immunology, Peking University, Beijing, China. He also contributes significantly to the Peking University Center for Human Disease Genomics. With a robust academic background in clinical and immunological sciences, Dr. Li’s research is focused on colitis-associated carcinogenesis and the molecular pathways that contribute to inflammatory bowel disease (IBD) and colorectal cancer. His recent milestone includes a first-author publication in the high-impact journal Cellular and Molecular Gastroenterology and Hepatology, coupled with a patent application for CMTM3 as a therapeutic target. Dr. Li has also presented his research at national congresses, underlining his capability in both lab innovation and scientific communication. His dedication to unraveling immune mechanisms promises meaningful breakthroughs in medical immunotherapy. 🌟
Professional Profile
🎓 Education
Dr. Rongbin Li pursued his Ph.D. in Immunology at the prestigious Peking University from 2019 to 2024, focusing on medical immunology and disease genomics. His academic journey was marked by exceptional research, culminating in a first-author publication and a nationally recognized patent. Prior to this, he earned a B.Med. in Clinical Medicine from Hebei University of Engineering (2014–2019), where he was trained in clinical diagnostics, pathophysiology, and foundational immunology. His educational progression reflects a strong foundation in both theoretical knowledge and experimental methodologies. Through rigorous coursework, extensive lab work, and early exposure to clinical sciences, Dr. Li has built a dual competence in clinical medicine and molecular immunology, making him uniquely positioned to bridge the gap between bedside and bench. His multidisciplinary academic background underpins his innovative contributions to immunotherapy and cancer research. 🎓🧪
💼 Experience
Dr. Li’s professional experience is deeply intertwined with cutting-edge immunological research at Peking University. During his doctoral tenure, he was entrusted with a National Natural Science Foundation of China (NSFC) funded project where he led experimental design, data analysis, and manuscript preparation. In collaboration with Peking University Third Hospital, he played a pivotal role in uncovering the mechanism of CMTM3 in aggravating colitis and promoting carcinogenesis, leading to a patent application. His responsibilities included conceptualization, methodology design, formal analysis, and software development, demonstrating expertise in both wet lab and computational environments. He also delivered an oral presentation at the 15th National Congress of Immunology (2023), showcasing his communication skills and subject mastery. His current research on therapeutic targets for IBD reflects a strong commitment to translational medicine. With a blend of lab skills, analytical capabilities, and cross-institutional teamwork, Dr. Li exemplifies the modern biomedical researcher. 🔬👨🔬
🔍 Research Interest
Dr. Rongbin Li’s core research interest revolves around colitis-associated carcinogenesis, with a focus on the immunological and molecular interactions that promote inflammatory bowel disease (IBD) and colorectal cancer. 🧫 His primary interest lies in deciphering the role of CMTM3, a novel therapeutic target that stabilizes CLTC and disrupts VE-cadherin regulation via clathrin-mediated pathways. His ongoing work investigates how immune and endothelial interactions exacerbate inflammatory responses and facilitate tumorigenesis. He also explores the mechanistic crosstalk between inflammation and epithelial-mesenchymal transition (EMT), with the broader goal of developing CMTM3-targeted biologics or small molecules. His interdisciplinary approach combines molecular immunology, cancer biology, and vascular biology, aimed at discovering actionable targets for precision medicine. By merging bioinformatics, cellular assays, and in vivo models, Dr. Li aspires to translate fundamental immunological discoveries into clinically viable therapies, particularly for patients suffering from chronic inflammation-related cancers. 🌐🧠
🏆 Awards
Dr. Rongbin Li’s promising contributions to immunology have garnered notable recognition. His recent work funded by the National Natural Science Foundation of China (NSFC) signifies his capability to lead and innovate in high-stakes research environments. 🧪 His first-author article in Cellular and Molecular Gastroenterology and Hepatology stands as a testament to his scholarly excellence, originality, and scientific rigor. In 2023, he was selected for an oral presentation at the 15th National Congress of Immunology, one of the most prestigious scientific forums in China. Additionally, his innovative findings led to a patent application titled “CMTM3 as a therapeutic target for IBD and colorectal cancer” (Appl. No: 2025104021503), demonstrating real-world impact and translational potential. These achievements position him as a strong candidate for the Best Researcher Award, celebrating his impactful early-career journey, commitment to scientific advancement, and potential for future breakthroughs in immunology and cancer therapy. 🏅
📚 Top Noted Publications
Dr. Rongbin Li’s scholarly work has made a significant impact in the field of immunology. His first-author research article, published in the reputable journal Cellular and Molecular Gastroenterology and Hepatology (2025), elucidates the critical role of CMTM3 in colitis-associated carcinogenesis. The study reveals how CMTM3 stabilizes CLTC and contributes to vascular endothelial dysfunction, advancing our understanding of inflammation-driven cancer mechanisms.
Key Findings
This research identifies CMTM3 (CKLF-like MARVEL transmembrane domain-containing 3) as a significant contributor to colitis-associated colorectal cancer (CAC). The study elucidates that CMTM3 stabilizes CLTC (clathrin heavy chain), enhancing clathrin-mediated endocytosis. This process leads to the internalization and degradation of VE-Cadherin, a crucial adhesion molecule in vascular endothelial cells. The loss of VE-Cadherin disrupts endothelial integrity, increasing vascular permeability, which exacerbates colitis and fosters a pro-inflammatory environment conducive to carcinogenesis.BioMed Central
Citation Information
As of the latest database update, this article has been cited by two other publications, indicating its emerging influence in the field of gastrointestinal oncology.
Related Research
Previous studies have explored the role of CMTM3 in various cancers. For instance, research has shown that CMTM3 can mediate angiogenesis by regulating the cell surface availability of VE-Cadherin in endothelial adherens junctions . These findings align with the current study’s observations on CMTM3’s impact on endothelial function and its potential role in cancer progression.
Conclusion
Dr. Rongbin Li shows exceptional promise as a medical immunologist with impactful research on colitis-associated cancer, underpinned by innovation (a therapeutic patent), prestigious institutional affiliation, and peer-reviewed publication. While citation metrics and broader scholarly visibility are still developing, the quality, novelty, and translational potential of his work make him well-suited for the Best Researcher Award.